Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.

Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F; ZEUS Study Investigators.

Lancet. 2011 Mar 5;377(9768):837-47. doi: 10.1016/S0140-6736(10)62318-5. Epub 2011 Feb 19. Erratum in: Lancet. 2012 Dec 8;380(9858):1994. Lancet. 2011 Jun 11;377(9782):2006. Wüthrich, Rudolf P [added].

PMID:
21334736
2.

Everolimus in patients with autosomal dominant polycystic kidney disease.

Walz G, Budde K, Mannaa M, Nürnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Hörl WH, Obermüller N, Arns W, Pavenstädt H, Gaedeke J, Büchert M, May C, Gschaidmeier H, Kramer S, Eckardt KU.

N Engl J Med. 2010 Aug 26;363(9):830-40. doi: 10.1056/NEJMoa1003491. Epub 2010 Jun 26. Erratum in: N Engl J Med. 2010 Sep 16;363(12):1190. N Engl J Med. 2010 Nov 11;363(20):1977.

3.

Neoimmun versus Neoral: a bioequivalence study in healthy volunteers and influence of a fat-rich meal on the bioavailability of Neoimmun.

Kees F, Bucher M, Schweda F, Gschaidmeier H, Faerber L, Seifert R.

Naunyn Schmiedebergs Arch Pharmacol. 2007 Aug;375(6):393-9. Epub 2007 Jun 15.

PMID:
17571254
4.

The neuronal 5-HT3 receptor network after 20 years of research--evolving concepts in management of pain and inflammation.

Faerber L, Drechsler S, Ladenburger S, Gschaidmeier H, Fischer W.

Eur J Pharmacol. 2007 Mar 29;560(1):1-8. Epub 2007 Jan 30. Review.

PMID:
17316606
5.

Comparative bioavailability of the microemulsion formulation of cyclosporine (Neoral) with a generic dispersion formulation (Cicloral) in young healthy male volunteers.

Kees F, Bucher M, Schweda F, Gschaidmeier H, Burhenne J, Mikus G, Faerber L.

Ther Drug Monit. 2006 Jun;28(3):312-20.

PMID:
16778713
6.

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

Wassmann B, Pfeifer H, Goekbuget N, Beelen DW, Beck J, Stelljes M, Bornhäuser M, Reichle A, Perz J, Haas R, Ganser A, Schmid M, Kanz L, Lenz G, Kaufmann M, Binckebanck A, Brück P, Reutzel R, Gschaidmeier H, Schwartz S, Hoelzer D, Ottmann OG.

Blood. 2006 Sep 1;108(5):1469-77. Epub 2006 Apr 25.

7.

Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation.

Millot F, Guilhot J, Nelken B, Leblanc T, De Bont ES, Békassy AN, Gadner H, Sufliarska S, Stary J, Gschaidmeier H, Guilhot F, Suttorp M.

Leukemia. 2006 Feb;20(2):187-92.

PMID:
16341042
8.

Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.

Hess G, Bunjes D, Siegert W, Schwerdtfeger R, Ledderose G, Wassmann B, Kobbe G, Bornhäuser M, Hochhaus A, Ullmann AJ, Kindler T, Haus U, Gschaidmeier H, Huber C, Fischer T.

J Clin Oncol. 2005 Oct 20;23(30):7583-93.

PMID:
16234522
9.

The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression.

Chen J, Röcken C, Nitsche B, Hosius C, Gschaidmeier H, Kahl S, Malfertheiner P, Ebert MP.

Cancer Lett. 2006 Feb 28;233(2):328-37.

PMID:
15893416
10.

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

Wassmann B, Pfeifer H, Stadler M, Bornhaüser M, Bug G, Scheuring UJ, Brück P, Stelljes M, Schwerdtfeger R, Basara N, Perz J, Bunjes D, Ledderose G, Mahlberg R, Binckebanck A, Gschaidmeier H, Hoelzer D, Ottmann OG.

Blood. 2005 Jul 15;106(2):458-63. Epub 2005 Apr 7.

11.

Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).

Kindler T, Breitenbuecher F, Kasper S, Estey E, Giles F, Feldman E, Ehninger G, Schiller G, Klimek V, Nimer SD, Gratwohl A, Choudhary CR, Mueller-Tidow C, Serve H, Gschaidmeier H, Cohen PS, Huber C, Fischer T.

Blood. 2005 Jan 1;105(1):335-40. Epub 2004 Sep 2.

12.

Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia.

Kindler T, Breitenbuecher F, Marx A, Beck J, Hess G, Weinkauf B, Duyster J, Peschel C, Kirkpatrick CJ, Theobald M, Gschaidmeier H, Huber C, Fischer T.

Blood. 2004 May 15;103(10):3644-54. Epub 2004 Jan 15.

13.

Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations.

Schleyer E, Pursche S, Köhne CH, Schuler U, Renner U, Gschaidmeier H, Freiberg-Richter J, Leopold T, Jenke A, Bonin M, Bergemann T, le Coutre P, Gruner M, Bornhäuser M, Ottmann OG, Ehninger G.

J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Jan 5;799(1):23-36.

PMID:
14659433
14.
15.

Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.

Pfeifer H, Wassmann B, Hofmann WK, Komor M, Scheuring U, Brück P, Binckebanck A, Schleyer E, Gökbuget N, Wolff T, Lübbert M, Leimer L, Gschaidmeier H, Hoelzer D, Ottmann OG.

Clin Cancer Res. 2003 Oct 15;9(13):4674-81.

16.

Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib.

Wassmann B, Pfeifer H, Scheuring UJ, Binckebanck A, Gökbuget N, Atta J, Brück P, Rieder H, Schoch C, Leimer L, Schwerdtfeger R, Ehninger G, Lipp T, Perz J, Stelljes M, Gschaidmeier H, Hoelzer D, Ottmann OG.

Blood. 2004 Feb 15;103(4):1495-8. Epub 2003 Oct 23.

17.

Current results on the use of imatinib mesylate in patients with relapsed Philadelphia chromosome positive leukemia after allogeneic or syngeneic hematopoietic stem cell transplantation.

Ullmann AJ, Hess G, Kolbe K, Friedrich-Freksa A, Meyer RG, Gschaidmeier H, Huber C, Fischer T.

Keio J Med. 2003 Sep;52(3):182-8.

18.

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.

Müller MC, Gattermann N, Lahaye T, Deininger MW, Berndt A, Fruehauf S, Neubauer A, Fischer T, Hossfeld DK, Schneller F, Krause SW, Nerl C, Sayer HG, Ottmann OG, Waller C, Aulitzky W, le Coutre P, Freund M, Merx K, Paschka P, König H, Kreil S, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.

Leukemia. 2003 Dec;17(12):2392-400.

PMID:
14523462
19.

Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).

Wassmann B, Scheuring U, Pfeifer H, Binckebanck A, Käbisch A, Lübbert M, Leimer L, Gschaidmeier H, Hoelzer D, Ottmann OG.

Leukemia. 2003 Oct;17(10):1919-24.

PMID:
14513038
20.

Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment.

Scheuring UJ, Pfeifer H, Wassmann B, Brück P, Gehrke B, Petershofen EK, Gschaidmeier H, Hoelzer D, Ottmann OG.

Leukemia. 2003 Sep;17(9):1700-6.

PMID:
12970767
21.

Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.

Paschka P, Müller MC, Merx K, Kreil S, Schoch C, Lahaye T, Weisser A, Petzold A, König H, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.

Leukemia. 2003 Sep;17(9):1687-94.

PMID:
12970765
22.

Imatinib in Philadelphia chromosome-positive chronic phase CML patients: molecular and cytogenetic response rates and prediction of clinical outcome.

Le Coutre P, Kreuzer KA, Na IK, Schwarz M, Lupberger J, Holdhoff M, Baskaynak G, Gschaidmeier H, Platzbecker U, Ehninger G, Prejzner W, Huhn D, Schmidt CA.

Am J Hematol. 2003 Aug;73(4):249-55.

23.

Normalization of previously shortened telomere length under treatment with imatinib argues against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with chronic myeloid leukemia.

Brummendorf TH, Ersoz I, Hartmann U, Balabanov S, Wolke H, Paschka P, Lahaye T, Berner B, Bartolovic K, Kreil S, Berger U, Gschaidmeier H, Bokemeyer C, Hehlmann R, Dietz K, Lansdorp PM, Kanz L, Hochhaus A.

Ann N Y Acad Sci. 2003 May;996:26-38.

PMID:
12799279
24.

In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.

Kindler T, Breitenbuecher F, Kasper S, Stevens T, Carius B, Gschaidmeier H, Huber C, Fischer T.

Leukemia. 2003 Jun;17(6):999-1009.

PMID:
12764361
25.

Imatinib restores expression of CD62L in BCR-ABL-positive cells.

Fruehauf S, Topaly J, Schad M, Paschka P, Gschaidmeier H, Zeller WJ, Hochhaus A, Ho AD.

J Leukoc Biol. 2003 May;73(5):600-3.

PMID:
12714574
26.

Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation.

Wassmann B, Scheuring U, Thiede C, Pfeifer H, Bornhäuser M, Griesinger F, Hochhaus A, Schleyer E, Gschaidmeier H, Hoelzer D, Ottmann OG.

Bone Marrow Transplant. 2003 Apr;31(7):611-4.

PMID:
12692630
27.

Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia.

Hofmann WK, Komor M, Wassmann B, Jones LC, Gschaidmeier H, Hoelzer D, Koeffler HP, Ottmann OG.

Blood. 2003 Jul 15;102(2):659-61. Epub 2003 Mar 27.

28.

Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia.

Brümmendorf TH, Ersöz I, Hartmann U, Bartolovic K, Balabanov S, Wahl A, Paschka P, Kreil S, Lahaye T, Berger U, Gschaidmeier H, Bokemeyer C, Hehlmann R, Dietz K, Lansdorp PM, Kanz L, Hochhaus A.

Blood. 2003 Jan 1;101(1):375-6. No abstract available.

29.

Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.

Kindler T, Breitenbuecher F, Marx A, Hess G, Gschaidmeier H, Gamm H, Kirkpatrick CJ, Huber C, Fischer T.

Blood. 2003 Apr 15;101(8):2960-2. Epub 2002 Dec 12.

30.

Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL).

Wassmann B, Pfeifer H, Scheuring U, Klein SA, Gökbuget N, Binckebanck A, Martin H, Gschaidmeier H, Hoelzer D, Ottmann OG.

Leukemia. 2002 Dec;16(12):2358-65.

31.

Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo.

Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhänel M, Spruss T, Bernhardt G, Graeff C, Färber L, Gschaidmeier H, Buschauer A, Fricker G.

J Clin Invest. 2002 Nov;110(9):1309-18.

32.

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.

Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R.

Leukemia. 2002 Nov;16(11):2190-6.

33.

Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia.

Burchert A, Wölfl S, Schmidt M, Brendel C, Denecke B, Cai D, Odyvanova L, Lahaye T, Müller MC, Berg T, Gschaidmeier H, Wittig B, Hehlmann R, Hochhaus A, Neubauer A.

Blood. 2003 Jan 1;101(1):259-64. Epub 2002 Jun 28.

34.

Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).

Scheuring UJ, Pfeifer H, Wassmann B, Bruck P, Atta J, Petershofen EK, Gehrke B, Gschaidmeier H, Hoelzer D, Ottmann OG.

Blood. 2003 Jan 1;101(1):85-90. Epub 2002 Aug 22.

35.

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.

Merx K, Müller MC, Kreil S, Lahaye T, Paschka P, Schoch C, Weisser A, Kuhn C, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.

Leukemia. 2002 Sep;16(9):1579-83.

36.

Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT).

Fischer T, Reifenrath C, Hess GR, Corsetti MT, Kreil S, Beck J, Meinhardt P, Beltrami G, Schuch B, Gschaidmeier H, Hehlmann R, Hochhaus A, Carella A, Huber C.

Leukemia. 2002 Jul;16(7):1220-8.

37.

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.

Hofmann WK, Jones LC, Lemp NA, de Vos S, Gschaidmeier H, Hoelzer D, Ottmann OG, Koeffler HP.

Blood. 2002 Mar 1;99(5):1860-2.

38.

Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study.

Hofmann WK, de Vos S, Elashoff D, Gschaidmeier H, Hoelzer D, Koeffler HP, Ottmann OG.

Lancet. 2002 Feb 9;359(9305):481-6.

PMID:
11853794
39.

Detection and separation of the S-adenosylmethionine-decarboxylase inhibitor SAM486A in human plasma and urine by reversed-phase ion-pairing high-performance liquid chromatography.

Kern W, Schleyer E, Bergmann M, Gschaidmeier H, Ehninger G, Hiddemann W, Braess J.

J Pharmacol Toxicol Methods. 2001 May-Jun;45(3):175-80.

PMID:
11755379
40.

Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation.

Wassmann B, Klein SA, Scheuring U, Pfeifer H, Martin H, Gschaidmeier H, Hoelzer D, Ottmann OG.

Bone Marrow Transplant. 2001 Oct;28(7):721-4.

41.

Density-dependent growth of normal and nodular hepatocytes.

Bock KW, Gschaidmeier H, Bock-Hennig BS, Eriksson LC.

Toxicology. 2000 Apr 3;144(1-3):51-6.

PMID:
10781870
42.

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)-mediated membrane translocation of c-Src protein kinase in liver WB-F344 cells.

Köhle C, Gschaidmeier H, Lauth D, Topell S, Zitzer H, Bock KW.

Arch Toxicol. 1999 Apr-May;73(3):152-8.

PMID:
10401681
43.

Functions and transcriptional regulation of PAH-inducible human UDP-glucuronosyltransferases.

Bock KW, Gschaidmeier H, Heel H, Lehmköster T, Münzel PA, Bock-Hennig BS.

Drug Metab Rev. 1999 May;31(2):411-22. Review.

PMID:
10335444
44.

Mono- and Diglucuronide formation from benzo[a]pyrene and chrysene diphenols by AHH-1 cell-expressed UDP-glucuronosyltransferase UGT1A7.

Bock KW, Raschko FT, Gschaidmeier H, Seidel A, Oesch F, Grove AD, Ritter JK.

Biochem Pharmacol. 1999 Mar 15;57(6):653-6.

PMID:
10037450
45.

AH receptor-controlled transcriptional regulation and function of rat and human UDP-glucuronosyltransferase isoforms.

Bock KW, Gschaidmeier H, Heel H, Lehmköster T, Münzel PA, Raschko F, Bock-Hennig B.

Adv Enzyme Regul. 1998;38:207-22.

PMID:
9762354
46.

Growth modulation of hepatocytes and rat liver epithelial cells (WB-F344) by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).

Münzel P, Bock-Hennig B, Schieback S, Gschaidmeier H, Beck-Gschaidmeier S, Bock KW.

Carcinogenesis. 1996 Feb;17(2):197-202.

PMID:
8625438
49.

Paracetamol glucuronidation by recombinant rat and human phenol UDP-glucuronosyltransferases.

Bock KW, Forster A, Gschaidmeier H, Brück M, Münzel P, Schareck W, Fournel-Gigleux S, Burchell B.

Biochem Pharmacol. 1993 May 5;45(9):1809-14.

PMID:
8494539
50.

Supplemental Content

Loading ...
Support Center